Richard T Maziarz

1 month ago | nature.com | Gabrielle Meyers |Mehdi Hamadani |Michael Martens |Haris Ali |Patrice Chevallier |Andrew Harris | +6 more

Correction to: Bone Marrow Transplantation https://doi.org/10.1038/s41409-023-02110-4, published online 25 September 2023In this article the funding support is correct within the paper but during the submission process, it appears that the wrong grant number was selected. This paper is a BMT CTN protocol only, and is not CIBMTR related. As such only the BMT CTN Grant number (U24HL138660) should be selected. The original article has been corrected.

Feb 28, 2024 | cco.amegroups.org | Andy Chen |Richard T Maziarz

Have a website account?Log In orRegister for exclusive website content. Home / Vol 13, No 1 (February 29, 2024) / Can we truly define ‘Fitness’ for CAR-T therapy in large B cell lymphoma patients? PDF 320 views Full Text 2 views Peer Review File 32 views COI Form 31 views

Dec 17, 2023 | nature.com | Philip L McCarthy |Amin M. Alousi |David Miklos |Ran Reshef |Richard T Maziarz |John Levine

AbstractIdentifying plasma biomarkers early after allo-HCT may become crucial to prevent and treat severe aGvHD. We utilized samples from 203 allo-HCT patients selected from the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) to identify new biomarker models to predict aGvHD and overall mortality. Two new biomarkers (Gal-3 and LAG-3), and previously identified biomarkers (ST2/IL33R, IL6, Reg3A, PD-1, TIM-3, TNFR1) were screened.

Sep 25, 2023 | nature.com | Gabrielle Meyers |Mehdi Hamadani |Michael Martens |Haris Ali |Patrice Chevallier |Andrew Harris | +6 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request....

Aug 22, 2023 | brnw.ch | Christopher Gibson |Laura Dillon |Joseph McGuirk |Richard T Maziarz

Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment for patients with myelodysplastic syndrome (MDS).